论文部分内容阅读
1962年起孕激素治疗晚期、复发的卵巢癌文献上有零星报导。1975～1981年作者对23例晚期复发的乳头状浆液性囊腺癌及1例盆腔间皮瘤术后放疗及化疗后的病人使用megestrol(一种长效孕激素)治疗,这些病人均有明显可触及的肿块或有X线阳性表现。根据FIGO分期,全部病人皆属Ⅱ期、Ⅳ期。组织学分级Ⅰ级4例,2级10例,3级9例。患者年龄17～79岁,其中46～65岁14例,65岁以上5例,45岁以下5例。megestrol治疗前,22例已作过手术及化疗(用环磷酰胺或马法兰),2例因有严重其他疾病未能手术而仅口服孕激素。肿瘤复发时,10例应用第二线化疗,2例放疗,5例再次行
Since 1962, progesterone treatment of advanced, recurrent ovarian cancer literature sporadic reports. From 1975 to 1981, the authors treated 23 patients with advanced papillary serous cystadenocarcinoma and 1 patient with postoperative pelvic mesothelioma post-chemotherapy with megestrol (a long-acting progestin), all of which were significantly Palpable mass or X-ray positive performance. According to FIGO staging, all patients are stage Ⅱ, Ⅳ. Histological grade Ⅰ grade in 4 cases, grade 2 in 10 cases, grade 3 in 9 cases. Patients aged 17 to 79 years, of which 46 to 65 years old in 14 cases, 5 years older than 65 years, 5 cases of 45 years of age. Before megestrol treatment, 22 patients had undergone surgery and chemotherapy (with cyclophosphamide or melphalan) and 2 patients had oral progestin alone because of serious illness. Tumor recurrence, 10 cases of second-line chemotherapy, radiotherapy in 2 cases, 5 cases again